1Sehmidt Ioanas M, Lode H. Treatment of pneumonia in: elderly patients[J]. Expert Opin Pharmaeother,2006,7 ( 5 ) :499- 507.
2Fernandez Sabe N, Carratala J, Roson B, et al.Community-acquired pneumonia in very elderly patients.causative organisms, clinical characteristics, and outcomes[ J ]. Medicine ( Baltimore ), 2003,82 ( 3 ):159-169.
3Ferrara A M,Fietta A M. New developments in antibacterial choice for lower respiratory tract infections in elderly patients [ J ]. Drugs Aging,2004,21 ( 3 ) :167 -186.
4Alan M,Fein M D. Pneumonia in the Elderly-Specical Diagnostic and Therapeutic Considerations[J]. Medical Clinics of North America, 1994,78 (5) : 101'5.
1BALFOUR JA, LAMB HM. Moxifloxacin:a review of its clinical potential in management of community-acquired respiratory tract infection[J]. Drugs, 2000, 59(1):115-139.
2HOEFFKEN G, MEYER HP. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithmmycin in the treatment of community-acquired pneumonia[J]. Respir Med, 2001,95(7) :553-564.
3American Thoracic Society. Guidelines for the management of adults with community acquired pneumonia [ J ] . Am J Respir Crit Care Med, 2001, 163(3) :1730-1754.
4NIEDERMAN MS. Guidelines for the management of community-acquired pneumonia[ J]. Med Clin North Am, 2001, 85 (5) : 1493-1509.
5MAN I, MURPHY J, FERGUSON J. Fluoroquinolone phototoxicity :a comparison of moxifloxaein and lomefloxaein in normal volunteers [ J ]. Antimierobial Chemotherapy, 1999,43 ( Suppl B) :77-82.
